We launched Pairnomix in 2016 with the goal of helping patients better understand their rare genetic mutation—and ultimately, to help their physicians discover potential new treatment options that are available today.
One of the most exciting developments in the study of rare diseases is genetic sequencing. As important as it is to identify the genetic mutation responsible for an individual’s mutation, that’s only the beginning. Pairnomix picks up where sequencing leaves off and provides highly personalized genetic evaluations of rare genetic mutations. Our services involve creating a laboratory model of an individual’s mutation, evaluating the mutation’s functional consequence, and testing more than 1,300 on-market drugs against the modeled mutation.
As a result, we can identify new drugs that may be effective for the individual’s rare genetic condition and advance his or her journey toward living a better life.
While we have begun our work within the epilepsy setting, we plan to expand our services and the indications we evaluate. We hope to provide valuable results to a variety of people as we pursue our mission of empowering individuals living with rare genetic conditions, as well as the physicians who treat them.
Matthew Fox, CEO